The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed

Blood

Volumn 118, Issue 4, 2011, Pages 946-954

  Popović, Jelena ^a,b   Li, Ang Ping ^a,b   Kloetzel, Peter Michael ^b   Leisegang, Matthias ^a   Uckert, Wolfgang ^a,c   Blankenstein, Thomas ^a,b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HYBRID PROTEIN; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1;

ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FUSION GENE; GENE CONSTRUCT; GENE EXPRESSION; GENE TRANSLOCATION; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 79960975523     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-12-325035     Document Type: Article

References (45)

1. Bendle GM, Haanen JB, Schumacher TN. Preclinical development of T cell receptor gene therapy. Curr Opin Immunol. 2009;21(2):209-214.
2. Muranski P, Restifo NP. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol. 2009;21(2):200-208.
3. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21(2):233-240.
4. Offringa R. Antigen choice in adoptive T-cell therapy of cancer. Curr Opin Immunol. 2009;21(2):190-199.
5. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114(3):535-546.
6. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event afterthe administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843-851.
7. Shurtleff SA, Buijs A, Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia. 1995;9(12):1985-1989. (Pubitemid 26023779)
8. Hong D, Gupta R, Ancliff P, et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science. 2008;319(5861):336- 339.
9. Schindler JW, Van Buren D, Foudi A, et al. TEL-AML1 corrupts hematopoietic stem cells to persist in the bone marrow and initiate leukemia. Cell Stem Cell. 2009;5(1):43-53.
10. Yotnda P, Garcia F, Peuchmaur M, et al. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J Clin Invest. 1998;102(2):455-462. (Pubitemid 28335206)
11. Viatte S, Alves PM, Romero P. Reverse immunology approach for the identification of CD8 T-celldefined antigens: advantages and hurdles. Immunol Cell Biol. 2006;84(3):318-330.
12. Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol. 2002;2(7):512-519. (Pubitemid 37328742)
13. Li LP, Lampert JC, Chen X, et al. Transgenic mice with a diverse human T cell antigen receptor repertoire. Nat Med. 2010;16(9):1029-1034.
14. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med. 1997;185(12):2043-2051. (Pubitemid 27265987)
15. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature. 1991;351(6324):290-296. (Pubitemid 21896578)
16. Engels B, Cam H, Schuler T, et al. Retroviral vectors for high-level transgene expression in T lymphocytes. Hum Gene Ther. 2003;14(12):1155-1168. (Pubitemid 36930405)
17. Garcia Casado J, Janda J, Wei J, et al. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo. Eur J Immunol. 2008;38(7):1867-1876.
18. Levy F, Johnsson N, Rumenapf T, Varshavsky A. Using ubiquitin to follow the metabolic fate of a protein. Proc Natl Acad Sci U S A. 1996;93(10):4907- 4912. (Pubitemid 26162845)
19. Chapatte L, Colombetti S, Cerottini JC, Levy F. Efficient induction of tumor antigen-specific CD8+ memory T cells by recombinant lentivectors. Cancer Res. 2006;66(2):1155-1160. (Pubitemid 43165985)
20. Morita S, Kojima T, Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 2000;7(12):1063-1066. (Pubitemid 30398356)
21. Zwaveling S, Ferreira Mota SC, Nouta J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated aftervaccination with long peptides. J Immunol. 2002;169(1):350-358. (Pubitemid 34686155)
22. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003;281(1-2):65-78. (Pubitemid 37324571)
23. McElroy DS, Badstibner AM, and D'Orazio, SE. Use of the CD107 mobilization assay reveals that cytotoxic T lymphocytes with novel MHC-Ib restriction are activated during Listeria monocytogenes infection. J Immunol Methods. 2007;328(1-2):45-52. (Pubitemid 350007616)
24. Casati C, Dalerba P, Rivoltini L, et al. The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res. 2003;63(15):4507-4515. (Pubitemid 36957896)
25. Kuckelkorn U, Ferreira EA, Drung I, Liewer U, Kloetzel PM, Theobald M. The effect of the interferon-gamma-inducible processing machinery on the generation of a naturally tumor-associated human cytotoxic T lymphocyte epitope within a wild-type and mutant p53 sequence context. Eur J Immunol. 2002;32(5):1368-1375. (Pubitemid 34546264)
26. Sun Y, Sijts AJ, Song M, et al. Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells. Cancer Res. 2002;62(10):2875-2882. (Pubitemid 34525774)
27. Zirlik KM, Zahrieh D, Neuberg D, Gribben JG. Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide. Blood. 2006;108(12):3865-3870. (Pubitemid 44864570)
28. Papanicolaou GA, Latouche JB, Tan C, et al. Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele. Blood. 2003;102(7):2498-2505. (Pubitemid 37193588)
29. Dupont J, Latouche JB, Ma C, Sadelain M. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res. 2005;65(12):5417- 5427. (Pubitemid 40827355)
30. Gomard E, Begue B, Sodoyer S, Maryanski JL, Jordan BR, Levy JP. Murine cells expressing an HLA molecule are specifically lysed by HLA-restricted antiviral human T cells. Nature. 1986;319(6049):153-154. (Pubitemid 16163590)
31. Shirai M, Arichi T, Nishioka M, et al. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J Immunol. 1995;154(6):2733-2742.
32. Alexander J, Oseroff C, Sidney J, et al. Derivation of HLA-A11/Kb transgenic mice: functional CTL repertoire and recognition of human A11-restricted CTL epitopes. J Immunol. 1997;159(10):4753-4761. (Pubitemid 127471010)
33. Firat H, Garcia-Pons F, Tourdot S, et al. H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur J Immunol. 1999;29(10):3112-3121. (Pubitemid 29484201)
34. Geluk A, van Meijgaarden KE, Franken KL, et al. Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLAA*0201-restricted CD8+ T cells in HLA-transgenic mice and humans. J Immunol. 2000;165(11):6463-6471.
35. Loirat D, Lemonnier FA, Michel ML. Multiepitopic HLA-A*0201- restricted immune response against hepatitis B surface antigen after DNA-based immunization. J Immunol. 2000;165(8):4748-4755.
36. Yang S, Linette GP, Longerich S, Roberts BL, Haluska FG. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL. Cell Immunol. 2000;204(1):29-37.
37. Kloetzel PM. Antigen processing by the proteasome. Nat Rev Mol Cell Biol. 2001;2(3):179-187.
38. Sijts AJ, Ruppert T, Rehermann B, Schmidt M, Koszinowski U, Kloetzel PM. Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes. J Exp Med. 2000;191(3):503-514.
39. Sijts EJ, Kloetzel PM. The role of the proteasome in the generation of MHC class I ligands and immune responses. Cell Mol Life Sci. 2011;68(9):1491-1502.
40. Schultz ES, Chapiro J, Lurquin C, et al. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J Exp Med. 2002;195(4):391-399. (Pubitemid 34461293)
41. Schwarz K, van Den Broek M, Kostka S, et al. Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1, but not PA28 alpha/beta, enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T cell epitope. J Immunol. 2000;165(2):768-778. (Pubitemid 30484743)
42. Sijts AJ, Standera S, Toes RE, et al. MHC class I antigen processing of an adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells. J Immunol. 2000;164(9):4500-4506. (Pubitemid 30238045)
43. Strehl B, Joeris T, Rieger M, et al. Immunoproteasomes are essential for clearance of Listeria monocytogenes in nonlymphoid tissues but not for induction of bacteria-specific CD8+ T cells. J Immunol. 2006;177(9):6238-6244. (Pubitemid 44642120)
44. Wilson DB, Wilson DH, Schroder K, et al. Specificity and degeneracy of T cells. Mol Immunol. 2004;40(14-15):1047-1055. (Pubitemid 38221185)
45. Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol. 1996;157(6):2539-2548. (Pubitemid 126450467)